Index. Note: Page numbers of article titles are in boldface type.

Size: px

Start display at page:

Download "Index. Note: Page numbers of article titles are in boldface type."

Gavin Manning
5 years ago
Views:

1 Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, in older early-stage breast cancer patients, anti-her2-directed therapy, chemotherapy, endocrine therapy, radiation therapy in invasive, selection of systemic, individualized, for luminal breast cancer, for luminal A disease, for luminal B disease, Ado-trastuzumab emtansine, for ERBB2-positive breast cancer, Age, of women with DCIS, impact on management, treatment challenges in older breast cancer patients, Amenorrhea, chemotherapy-related, in breast cancer survivors, osteoporosis due to, sexual dysfunction due to, vasomotor symptoms due to, Anastrozole, breast cancer prevention by, Androgen receptor signaling, inhibition of, for treating advanced triple-negative breast cancer, 745 Antiandrogens, overcoming endocrine resistance with, Antiangiogenic strategies, for advanced triple-negative breast cancer, Antibody-drug conjugates, for ERBB2-positive breast cancer, Aromatase inhibitors, breast cancer prevention by, anastrozole, exemestane, 665 for advanced/metastatic breast cancer, era of adjuvant, exemestane after nonsteroidal, fulvestrant, tamoxifen after, 719 first-line, compared with tamoxifen therapy, second-line, after tamoxifen therapy, 717 tamoxifen therapy without prior adjuvant, tamoxifen for advanced/metastatic breast cancer without prior adjuvant, Arzoxifene, breast cancer prevention by, 664 Aspirin, breast cancer prevention by, Axilla, management in breast cancer patients, occult metastases, sentinel lymph node biopsy in, completion axillary lymph node dissection after positive, contraindications to, 694 Hematol Oncol Clin N Am 27 (2013) hemonc.theclinics.com /13/$ see front matter ª 2013 Elsevier Inc. All rights reserved.

2 862 Axilla (continued) history of, indications for, technical aspects of, Axillary lymph node dissection, completion, after positive SLNB in breast cancer patients, B B-cell receptor inhibitor, ibrutinib in chronic lymphocytic leukemia, Biomarker studies, identifying breast cancer patients with better chance of neoadjuvant treatment benefit, Biopsy, sentinel lymph node. See Sentinel lymph node biopsy. Bone metastases, in older breast cancer patients, 798 BRCA mutation, association of triple-negative breast cancer with, 739 Breast cancer, axilla, management of, occult metastases, sentinel lymph node biopsy in, completion axillary lymph node dissection after positive, contraindications to, 694 history of, indications for, technical aspects of, cost and value of treatment, assessing value of medical treatments, controlling costs of care, how much is spent, making cost decisions, endocrine therapy for advanced/metastatic, aromatase inhibitors, for premenopausal patients with metastatic, other options, overcoming resistance to, tamoxifen and others without prior adjuvant aromatase inhibitors, evaluating use of neoadjuvant therapy for, assessment of residual disease for prognosis, diagnosis of pathologic complete response and prognosis by subtypes, in patients with pathologic complete response of locally advanced tumors, interim response-guided treatment in lower risk subtypes, no invasive residuals in breast and nodes, translational biomarker studies, in evaluating use of neoadjuvant therapy for, in older patients, treatment challenges in, clinical trials, DCIS, defining goals of treatment, early-stage, estimating survival and geriatric assessment, metastatic, palliative care and hospice, 798

3 863 predicting chemotherapy toxicity, 789 luminal, tailoring adjuvant treatments for, for luminal A disease, for luminal B disease, pathway-based care, development and delivery of, differences from guidelines, 844 factors leading to development of, 844 overview, results of use of, 849 treatment patterns resulting from, Via Pathways at UPMC Cancer Center, prevention by antihormones and other drugs, aromatase inhibitors, other drugs, selective estrogen receptor modulators, radiation therapy for ductal carcinoma in situ, in asymptomatic patients, in patients with symptoms, 682 technique, 684 with tamoxifen, survivorship issues, bothersome symptoms, organizing follow-up care, surveillance of survivors, treatment-related cancers, 818 treating the HER2 pathway in early and advanced, current disease management summary, future directions, 761 with antibody-drug conjugate ado-trastuzumab emtansine, with combined ERBB2-targeting agents and endocrine therapy, with lapatinib plus trastuzumab, with pertuzumab, triple-negative, management of early-stage and metastatic, future directions, 745 overview, therapeutic options for advanced, therapeutic options for early stage, unique biology of, Bruton tyrosine kinase inhibitor, ibrutinib in chronic lymphocytic leukemia, C Cancers, treatment-related, in breast cancer survivors, 818 Cardiac toxicity, in breast cancer survivors, Chemoprevention, of breast cancer, aromatase inhibitors, anastrozole, exemestane, 665 other drugs,

4 864 Chemoprevention (continued) aspirin, metformin, selective estrogen receptor modulators, lasofoxifene, raloxifene, tamoxifen, Chemotherapy, amenorrhea related to in breast cancer survivors, osteoporosis due to, sexual dysfunction due to, vasomotor symptoms due to, in older breast cancer patients, , adjuvant, in early-stage disease, in metastatic disease, of triple-negative breast cancer, advanced, early stage, predicting toxicity of in older breast cancer patients, 789 vasomotor symptoms in breast cancer survivors due to amenorrhea from, Chronic lymphocytic leukemia (CLL), ibrutinib (PCI-32765) in, clinical studies, preclinical studies, Clinical trials, older breast cancer patients and, CLL. See Chronic lymphocytic leukemia. Cognitive changes, in breast cancer survivors, Costs, and value of breast cancer treatment, assessing value of medical treatments, controlling costs of care, how much is spent, making cost decisions, D DCIS. See Ductal carcinoma in situ. Ductal carcinoma in situ (DCIS), in older breast cancer patients, radiation therapy for, in asymptomatic patients, age, grade, size, and other disease factors, margin issues, markers for predicting recurrence, in patients with symptoms, 682 technique, 684 with tamoxifen, SNLB in patients with, E Elderly. See Geriatrics. Endocrine therapy, combined with ERBB2-targeting agents, for advanced/metastatic breast cancer,

5 865 aromatase inhibitors, exemestane after nonsteroidal, first line compared with tamoxifen, fulvestrant, second-line after tamoxifen, 717 for premenopausal patients with metastatic, other options, progestins and estrogens, overcoming resistance to, antiandrogens, combination therapy with anti-her2 agents in HER2-positive cases, combination wioth mtor inhibitors, combinations with histone deacetylase inhibitors, 726 tamoxifen and others without prior adjuvant aromatase inhibitors, high-dose estrogens, progestins, oophorectomy, and other SERMs, in older breast cancer patients, , 797 in early-stage disease, in metastatic disease, 797 in patients with luminal breast cancer, novel strategies to overcome resistance to, Epithelial growth factor receptor, inhibition of, for treating advanced triple-negative breast cancer, 744 ERBB2 targeted therapy, in early and advanced breast cancer, combined with endocrine therapy, current disease management summary, future directions, 761 with antibody-drug conjugate ado-trastuzumab emtansine, with lapatinib plus trastuzumab, with pertuzumab, Estrogen receptor (ER) modulators, selective. See Selective estrogen receptor modulators. Estrogens, for advanced/metastatic breast cancer, Exemestane, breast cancer prevention by, 665 for advanced/metastatic breast cancer, F Fatigue, in breast cancer survivors, 815 Fulvestrant, for advanced/metastatic breast cancer, G Gene assays, in patients with endocrine-resistance luminal breast cancer, Geriatrics, treatment challenges in older breast cancer patients, clinical trials, DCIS, defining goals of treatment, early-stage, estimating survival and geriatric assessment, metastatic, palliative care and hospice, 798 predicting chemotherapy toxicity, 789

6 866 H HER2 pathway, targeting of, in early and advanced breast cancer, current disease management summary, future directions, 761 in older patients, , 798 adjuvant, in early-stage disease, in metastatic disease, 798 with antibody-drug conjugate ado-trastuzumab emtansine, with combined ERBB2-targeting agents and endocrine therapy, with lapatinib plus trastuzumab, with pertuzumab, Histone deacetylase inhibitors, endocrine therapy in combination with, 726 Hormonal therapy, symptoms related to, in breast cancer survivors, infertility and delayed childbearing due to, musculoskeletal complaints related to, osteoporosis due to, sexual dysfunction, vasomotor symptoms, Hospice, for older breast cancer patients, 798 I Ibrutinib (PCI-32765), in chronic lymphocytic leukemia (CLL), clinical studies, preclinical studies, Infertility, treatment-related, in breast cancer survivors, Inflammatory breast cancer, contradiction for SLNB in, 696 L Lapatinib, plus trastuzumab for dual targeting of ERBB2 receptor, Lasofoxifene, breast cancer prevention by, Leukemia, chronic lymphocytic (CLL), ibrutinib (PCI-32765) in, clinical studies, preclinical studies, Luminal breast cancer, tailoring adjuvant treatments for, for luminal A disease, for luminal B disease, Lymph node biopsy, sentinel. See Sentinel lymph node biopsy. Lymph node dissection, axillary. See Axillary lymph node dissection. Lymphocytic leukemia, chronic (CLL), ibrutinib (PCI-32765) in, clinical studies, preclinical studies, M Margins, in DCIS, impact on management, Markers, for recurrence in DCIS, impact on management, Mastectomy, SLNB in patients undergoing prophylactic, Metastatic breast cancer, endocrine therapy for, in older patients,

7 867 anti-her2 therapy in, 798 bone metastases, 798 chemotherapy in, endocrine therapy in, 797 goals of treatment, radiation therapy in, 797 occult, role of SLNB in, Metformin, breast cancer prevention by, mtor inhibitors, endocrine therapy in combination with, Musculoskeletal complaints, treatment-related, in breast cancer survivors, N Neoadjuvant therapy, for breast cancer, evaluating potential use of, assessment of residual disease for prognosis, diagnosis of pathologic complete response and prognosis by subtypes, in patients with pathologic complete response of locally advanced tumors, interim response-guided treatment in lower risk subtypes, no invasive residuals in breast and nodes, translational biomarker studies, for early-stage triple-negative breast cancer, SLNB in patients undergoing, Neuropathy, in breast cancer survivors, O Occult metastases, in breast cancer, role of SLNB in, Older patients. See Geriatrics. Osteoporosis, treatment-related, in breast cancer survivors, P Palliative care, for older breast cancer patients, 798 Pathologic complete response, in evaluating for potential use of neoadjuvant therapy for breast cancer, Pathway-based care, development and delivery of, differences from guidelines, 844 factors leading to development of, 844 overview, results of use of, 849 treatment patterns resulting from, Via Pathways at UPMC Cancer Center, PCI See Ibrutinib. Pertuzumab, for ERBB2-positive breast cancer, Poly-ADP-ribose polymerase, inhibition of, for treating advanced triple-negative breast cancer, 744 Pregnancy-associated breast cancer, contradiction for SLNB in, 696 Premenopausal patients, with metastatic breast cancer, endocrine therapy for, Prevention, of breast cancer, aromatase inhibitors, anastrozole, exemestane, 665

8 868 Prevention (continued ) other drugs, aspirin, metformin, selective estrogen receptor modulators, lasofoxifene, raloxifene, tamoxifen, Progestins, for advanced/metastatic breast cancer, Prophylactic mastectomy, SLNB in patients undergoing, R Radiation therapy, for ductal carcinoma in situ, in asymptomatic patients, age, grade, size, and other disease factors, margin issues, markers for predicting recurrence, in patients with symptoms, 682 technique, 684 with tamoxifen, for early-stage triple-negative breast cancer, in older breast cancer patients, , 797 adjuvant, in early stage disease, in metastatic disease, 797 Raloxifene, breast cancer prevention by, S Selective estrogen receptor modulators, breast cancer prevention by, lasofoxifene, raloxifene, tamoxifen, Sentinel lymph node biopsy, in breast cancer patients, completion axillary lymph node dissection after positive, contraindications to, 694 inflammatory breast cancer, 694 pregnancy-associated breast cancer, 694 history of, indications for, clinically palpable axillary lymph nodes, 692 DCIS, multicentric lesions, 692 neoadjuvant chemotherapy, previous breast or axillary surgery, 691 prophylactic mastectomy, technical aspects of, Sexual dysfunction, treatment-related, in breast cancer survivors,

9 869 SLNB. See Sentinel lymph node biopsy. Surveillance, of survivors of breast cancer, Survival, estimation of, in older breast cancer patients, Survivorship issues, in breast cancer, bothersome symptoms, organizing follow-up care, surveillance of survivors, treatment-related cancers, 818 T Tamoxifen, breast cancer prevention by, for advanced/metastatic breast cancer without prior adjuvant aromatase inhibitors, Targeted therapy, for advanced triple-negative breast cancer, in ERBB2-positive early and advanced breast cancer, combined with endocrine therapy, current disease management summary, future directions, 761 with antibody-drug conjugate ado-trastuzumab emtansine, with lapatinib plus trastuzumab, with pertuzumab, Trastuzumab, in antibody-drug conjugate for ERBB2-positive breast cancer, plus lapatinib for dual targeting of ERBB2 receptor, Triple-negative breast cancer, management of early-stage and metastatic, future directions, 745 overview, therapeutic options for advanced, principles of systemic therapy, targeted agents, therapeutic options for early stage, local therapy/radiation therapy, systemic therapy/neoadjuvant and adjuvant therapy, unique biology of, association with BRCA mutations, 739 U University of Pittsburgh Medical Center (UPMC), development and use of Via Pathways at, V Value, and costs of breast cancer treatment, assessing value of medical treatments, controlling costs of care, how much is spent, making cost decisions, Vasomotor symptoms, in breast cancer survivors, Via Pathways, development and use of at UPMC Cancer Center, W Weight gain, in breast cancer survivors, 814

Breast Cancer. Dr. Andres Wiernik 2017

Breast Cancer. Dr. Andres Wiernik 2017 Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk